BPC-157 and Tesamorelin Interaction

Synergistic
Mechanism-based 55% confidence

BPC-157 and Tesamorelin have a synergistic interaction with 55% confidence. BPC-157 and Tesamorelin work through complementary pathways. Growth hormone signaling supports tissue repair processes. A well-established combination in recovery protocols. These compounds primarily affect different organ systems.

Compound Profiles

BPC-157

Body Protection Compound-157 | Pentadecapeptide

Promotes blood vessel formation (angiogenesis), enhances collagen synthesis, modulates growth factor expression including VEGF, and protects against tissue damage through localized or systemic delivery pathways..

Half-life: <30 minutes Typical dose: 250-500mcg healing, longevity
vegf anticoagulantcarcinogenic riskpro angiogenicteratogenic
View full profile

Tesamorelin

GHRH Analog | Visceral Fat Reduction

Subcutaneous injection provides optimal bioavailability for GHRH receptor binding and pulsatile GH release stimulation, selectively targeting visceral adipose tissue while sparing subcutaneous fat..

Half-life: 26-38 minutes Typical dose: 1.4-2mg daily (FDA-approved: 2mg for HIV lipodystrophy) growth hormone, weight loss
ghrh receptor carcinogenic riskinsulin disruptingteratogenic
View full profile

Combined Organ Load

Blood Vessels
low
GI Tract
low
Pituitary
low

Shared Safety Flags

2x 2 compounds share the carcinogenic-risk safety flag (BPC-157, Tesamorelin). Monitor accordingly.
2x 2 compounds share the teratogenic safety flag (BPC-157, Tesamorelin). Monitor accordingly.

Frequently Asked Questions

Can I take BPC-157 with Tesamorelin?

Yes, BPC-157 and Tesamorelin can generally be taken together. BPC-157 and Tesamorelin work through complementary pathways. Growth hormone signaling supports tissue repair processes. A well-established combination in recovery protocols.

Is BPC-157 and Tesamorelin safe together?

Based on pharmacological analysis, this combination is considered synergistic. However, shared safety flags include: carcinogenic risk, teratogenic. Monitor accordingly.

What are the interactions between BPC-157 and Tesamorelin?

BPC-157 and Tesamorelin work through complementary pathways. Growth hormone signaling supports tissue repair processes. A well-established combination in recovery protocols. This assessment has 55% confidence and is inferred from pharmacological mechanism analysis.

How should I time BPC-157 and Tesamorelin?

BPC-157 has a half-life of <30 minutes and Tesamorelin has a half-life of 26-38 minutes. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: BPC-157 vs Tesamorelin

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.